ATE496025T1 - Magnesiumsalze von hmg-coa-reduktase-hemmern - Google Patents

Magnesiumsalze von hmg-coa-reduktase-hemmern

Info

Publication number
ATE496025T1
ATE496025T1 AT06765662T AT06765662T ATE496025T1 AT E496025 T1 ATE496025 T1 AT E496025T1 AT 06765662 T AT06765662 T AT 06765662T AT 06765662 T AT06765662 T AT 06765662T AT E496025 T1 ATE496025 T1 AT E496025T1
Authority
AT
Austria
Prior art keywords
magnesium salts
hmg
coa reductase
reductase inhibitors
compositions
Prior art date
Application number
AT06765662T
Other languages
English (en)
Inventor
Yatendra Kumar
Saridi Madhava Dileep Kumar
Swargam Sathyanarayana
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE496025(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of ATE496025T1 publication Critical patent/ATE496025T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06765662T 2005-05-03 2006-05-03 Magnesiumsalze von hmg-coa-reduktase-hemmern ATE496025T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1108DE2005 2005-05-03
PCT/IB2006/051396 WO2006117761A2 (en) 2005-05-03 2006-05-03 Magnesium salts of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
ATE496025T1 true ATE496025T1 (de) 2011-02-15

Family

ID=37308379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06765662T ATE496025T1 (de) 2005-05-03 2006-05-03 Magnesiumsalze von hmg-coa-reduktase-hemmern

Country Status (9)

Country Link
US (1) US20100222405A1 (de)
EP (2) EP2172452A1 (de)
AT (1) ATE496025T1 (de)
DE (1) DE602006019710D1 (de)
DK (1) DK1879862T3 (de)
ES (1) ES2304911T3 (de)
NO (1) NO20076191L (de)
PT (1) PT1879862E (de)
WO (1) WO2006117761A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1957452E (pt) 2005-11-21 2010-05-25 Warner Lambert Co Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
CA2631549A1 (en) * 2005-11-29 2007-06-07 Biocon Limited Polymorphs of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l-heptanoic acid magnesium salt (2: 1)
WO2007099552A2 (en) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
IS8587A (is) * 2006-12-27 2008-06-28 Actavis Group Hf. Atorvastatin lyfjasamsetning
WO2009063476A1 (en) * 2007-11-16 2009-05-22 Biocon Limited A crystalline form of atorvastatin hemi magnesium salt and a process thereof
EP2130819A3 (de) 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Kristalline Formen von Atorvastatin-Magnesium
WO2009157005A1 (en) * 2008-06-26 2009-12-30 Biocon Limited Crystalline forms of atorvastatin hemi-magnesium salt and a process thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
AP2004003112A0 (en) 2002-02-14 2004-09-30 Ranbaxy Lab Ltd Formulations of atorvastatin stabilised with alkali metal additions
CA2588216A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
EP1833466A1 (de) * 2004-12-28 2007-09-19 Ranbaxy Laboratories Limited Verfahren zur herstelulng von stabilen pharmazeutischen soliden dosierformen von atorvastatin und amlodipin
MX2007009281A (es) * 2005-02-10 2007-09-25 Lufecycle Pharma As Composicion farmaceutica estable que comprende una combinacion de dosis fija de fenofibrato y un inhibidor de 3-hidroxi 3-metilglutaril-coenzima a reductasa.
PT1957452E (pt) * 2005-11-21 2010-05-25 Warner Lambert Co Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
CA2631549A1 (en) * 2005-11-29 2007-06-07 Biocon Limited Polymorphs of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l-heptanoic acid magnesium salt (2: 1)
WO2007099552A2 (en) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
EP2016048A4 (de) * 2006-05-11 2010-06-23 Biocon Ltd Kristalline form b4 von atorvastatin-magnesium und verfahren dafür
EP2130819A3 (de) * 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Kristalline Formen von Atorvastatin-Magnesium

Also Published As

Publication number Publication date
ES2304911T3 (es) 2011-05-30
EP1879862A2 (de) 2008-01-23
WO2006117761A2 (en) 2006-11-09
ES2304911T1 (es) 2008-11-01
NO20076191L (no) 2008-01-30
EP2172452A1 (de) 2010-04-07
PT1879862E (pt) 2011-04-19
US20100222405A1 (en) 2010-09-02
DK1879862T3 (da) 2011-05-16
DE602006019710D1 (de) 2011-03-03
EP1879862B1 (de) 2011-01-19
WO2006117761A3 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
ATE496025T1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
WO2012002741A3 (en) Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
SG166829A1 (en) Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007015866A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
WO2007015877A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
TNSN05306A1 (en) Substituted pyrrole derivatives.
MX2009003981A (es) Agentes moduladores del receptor de calcio.
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
EA200601678A1 (ru) Новые имидазолы
DK2363130T3 (da) Kombination af HMG-CoA reduktaseinhibitorer atorvastatin eller simvastatin med en phosphodiesterase 4-inhibitor, såsom roflumilast til behandlingen af inflammatorisk pulmonære sygdomme
NO20043919L (no) Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater
BRPI0506865A (pt) inibidores de hmg-coa redutase inusitados, baseados em imidazóis
EA200801666A1 (ru) КОМБИНАЦИЯ ПРОИЗВОДНЫХ ТРИАЗИНА И ИНГИБИТОРОВ HMG-CoA РЕДУКТАЗЫ
GR20050100466A (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1879862

Country of ref document: EP